Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023 | Psychedelic Invest

ncannex Healthcare Limited (Nasdaq: IXHL / ASX: IHL), a pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic therapies for unmet medical needs, is pleased to announce that it will be featured as a presenting company at the H.C. Wainwright 4^th Annual Neuropsychiatry Virtual Conference. The conference is being held virtually on September 26, 2023.

Joel Latham, CEO of Incannex, will provide an overview of the Company’s business during the presentation.

If you are an institutional investor and would like to listen to the Company’s presentation or request a 1×1 meeting, please click on the following link (https://hcwevents.com/neuropsychiatry-conference/) to register for the conference.

Event: H.C. Wainwright 4^th Annual Neuropsychiatry Virtual Conference

Date: June 26, 2023

1×1 virtual meeting availability: June 26, 2023, 2:00-5:00pm (U.S. eastern time)

Time/Location: Virtual to start on-demand June 26^th at 7:00am (U.S. eastern time)

About Incannex Healthcare Limited

Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.

U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities to Incannex and its shareholders.

Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds 19 granted patents and 30 pending patent applications.

Q&A: Why the NIH is spending $30 million to counter ableism in health care

A new NIH program will allocate nearly $30 million to 10 groups over five years to examine the impact of ableism on various health outcomes for

October 8, 2024

Patients affected by depression more likely to stop taking their heart medications

Patients who feel low when having a cardiac device implanted are more likely to stop taking their heart medications than those without depression, according to

June 25, 2023

Novo’s oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.